Should an adult aged 50 years or older receive the recombinant zoster vaccine (Shingrix), and what are the dosing schedule, contraindications, and recommendations for immunocompromised patients or those with prior Zostavax?

Shingles Vaccine Recommendation

Adults aged 50 years or older should receive the recombinant zoster vaccine (Shingrix/RZV) as a 2-dose series administered 2-6 months apart, regardless of prior herpes zoster history or previous Zostavax vaccination. 1

Dosing Schedule

The standard regimen consists of:

• Two 0.5 mL intramuscular doses separated by 2-6 months (minimum interval: 4 weeks) 2, 1
• For immunocompromised adults aged ≥18 years at increased risk, a shortened interval of 1-2 months between doses may be considered if they would benefit from faster protection 3
• If the second dose is administered too soon (before 4 weeks), it should be repeated 2

Age-Based Recommendations

Adults 50-59 Years

• RZV is FDA-approved and recommended for routine use starting at age 50 1, 4
• The older 2014 guidelines referenced live zoster vaccine (Zostavax) with weaker recommendations for ages 50-59 5, but these are superseded by current RZV recommendations

Adults ≥60 Years

• Strong recommendation for RZV vaccination 6, 2
• RZV is preferred over the older live zoster vaccine (Zostavax) due to superior and more durable efficacy 7, 8

Prior Zostavax Recipients

Patients who previously received Zostavax (live zoster vaccine) should still receive the full 2-dose RZV series, administered at least 2 months after the last Zostavax dose 3, 2, 7. This recommendation is based on:

• RZV demonstrates superior vaccine efficacy that remains stable over time, while Zostavax efficacy decreases with age and time since vaccination 7
• Real-world data shows 73.9% effectiveness against herpes zoster and 83.7% effectiveness against postherpetic neuralgia with 2 RZV doses 8
• Nearly half (46.7%) of vaccinated individuals in effectiveness studies had previously received Zostavax without safety concerns 8

Prior Herpes Zoster History

Vaccination is recommended even in patients with a history of shingles, as RZV prevents recurrent episodes 6, 7. Consider waiting approximately 1 year after an acute herpes zoster episode before administering RZV, though this timing is discretionary 7.

Immunocompromised Patients

This represents a critical update from older guidelines. RZV is now recommended for immunocompromised adults aged ≥19 years who are or will be at increased risk due to disease or therapy 3, 9, 10. This is a major departure from previous contraindications.

Key Points for Immunocompromised Patients:

• RZV (recombinant vaccine) is safe in immunocompromised individuals, unlike the live Zostavax which remains contraindicated 9, 11
• FDA expanded RZV indication in 2021 to include immunocompromised adults ≥18 years 9
• Includes patients with: HIV infection, hematopoietic stem cell transplant recipients, solid organ transplant recipients, those on immunosuppressive therapy, and patients with primary immunodeficiency disorders 3, 9, 10
• 88% of VZV-seronegative immunocompromised patients mounted significant antibody responses after RZV vaccination 10

Timing Considerations:

• Ideally administer ≥4 weeks before starting highly immunosuppressive therapy when possible 5, 12
• Can be given to patients on low-level immunosuppression 5
• For urgent immunosuppressive treatments, do not delay therapy for vaccination 12

Contraindications

Absolute contraindications:

• Pregnancy (consider delaying until after delivery) 2, 1
• Severe allergic reaction to any vaccine component 1
• Acute moderate-to-severe illness (defer until recovery) 1

Important distinction: Unlike Zostavax, RZV is NOT contraindicated in immunocompromised patients 9, 11.

Clinical Effectiveness

Recent real-world data demonstrates:

• 73.9% effectiveness against herpes zoster (95% CI: 71.8%-75.8%) 8
• 83.7% effectiveness against postherpetic neuralgia (95% CI: 75.1%-89.3%) 8
• 72.9% effectiveness against herpes zoster ophthalmicus (67.0%-77.8%) 13
• Protection remains stable over 4 years post-vaccination 8
• Associated with 28% lower risk of acute myocardial infarction and 42.5% lower risk of stroke 13

Single-Dose Considerations

While one dose provides some protection (60.3% effectiveness against herpes zoster), completion of the 2-dose series is essential for optimal protection 8. Single-dose effectiveness against postherpetic neuralgia is substantially lower at 45.6% 8.

Common Pitfalls to Avoid

1. Do not withhold RZV from immunocompromised patients thinking it's contraindicated—this applies only to the old live vaccine (Zostavax) 9
2. Do not skip vaccination in patients with prior shingles—they remain at risk for recurrence 7
3. Do not consider Zostavax recipients as "already vaccinated"—they should receive the full RZV series 7
4. Do not administer doses closer than 4 weeks apart—if given too early, repeat the dose 2
5. Ensure proper reconstitution—RZV requires mixing two vials (lyophilized antigen + adjuvant suspension) and must be used within 6 hours 1